Percutaneous aortic valve replacement

Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer

Retrieved on: 
Monday, March 25, 2024
Mechanical, SAS, American Heart Association, Percutaneous aortic valve replacement, Product marketing, Abbott Laboratories, Massachusetts Institute of Technology, Business, Patient, Business development, LAA, Medtronic, MD, Senior, Master, Retirement, TAVR, Marketing, Management

Paris, France and Munich, Germany, March 25, 2024 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer (CEO).

Key Points: 
  • Paris, France and Munich, Germany, March 25, 2024 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer (CEO).
  • In conjunction with this, and following eight years at the helm of the business, Helmut Straubinger is retiring as President & CEO.
  • Ahmed Elmouelhi is a seasoned professional with more than 20 years of medical device experience across strategy, sales and marketing, R&D, and clinical science.
  • Before joining TRiCares, Ahmed served as the Senior Vice President of Product Marketing, Strategy, and Business Development at AtriCure.

Transverse Medical Appoints David C. Blowers to Board of Directors, Dr. Rahul Sharma as Independent Member, Carl St. Bernard rejoins Board.

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Biotechnology, General Health, Health, Hospitals, Health Technology, Clinical Trials, Other Health, Percutaneous aortic valve replacement, Government, Entrepreneurship, Associate, Intelligence, Abbott Laboratories, Kellogg School, FRACP, Risk, Lawrence University, Cardiac catheterization, Russian Imperial Guard, MBBS, MD, MBA, GE HealthCare, Johnson & Johnson, Mission, TAVR, Stanford University, Heart, Vice, Corporation

Transverse Medical is pleased to announce the appointment of David C. Blowers to the Board of Directors.

Key Points: 
  • Transverse Medical is pleased to announce the appointment of David C. Blowers to the Board of Directors.
  • Carl St. Bernard has been reinstated as an independent member to the Board of Directors; Mr. St. Bernard first joined the company in March of 2021 and has served as an Executive Advisor and Board Director.
  • Rahul P. Sharma, MD, has joined the Board of Directors as an independent member and will also Chair the Medical Advisory Board.
  • Mr. David C. Blowers is an experienced wealth management and finance professional, board director, C-Suite Executive, and currently serves as Vice Chairman of Northern Trust.

Endologix Appoints Mike Mathias as Chief Commercial Officer

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, TAVR, MD, Strategic planning, MBA, Percutaneous aortic valve replacement, University, Vascular disease, Peripheral artery disease, Organization, Medtronic, EVAR, Endovascular aneurysm repair

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.
  • With a distinguished 30-year career in leading commercial organizations within the cardiovascular arena, Mike brings a wealth of experience and a proven track record of success to Endologix.
  • Mike is uniquely qualified to lead our global commercial team and continue the strategic development of our commercial plans.
  • In response to his new role, Mike Mathias shared, "Joining Endologix at such a critical juncture is an honor.

Pi-Cardia Receives FDA Breakthrough Device Designation for ShortCut™

Retrieved on: 
Monday, January 22, 2024
Health, FDA, Medical Devices, Health Technology, Other Health, Cardiology, Biotechnology, Patient, Hemodynamics, MD, Percutaneous aortic valve replacement, Aortic stenosis, TMVR, Risk, Food, Morristown Medical Center, Heart, TAVR, Diagnosis, Medical device

Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it received Breakthrough Device Designation from the US Food and Drug Administration for ShortCut™ - the world's first dedicated leaflet modification device facilitating valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures in patients at risk of coronary obstruction.

Key Points: 
  • Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it received Breakthrough Device Designation from the US Food and Drug Administration for ShortCut™ - the world's first dedicated leaflet modification device facilitating valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures in patients at risk of coronary obstruction.
  • This announcement comes after completion of enrollment in the ShortCut™ Pivotal Study in the US and Europe in September 2023.
  • “Having been part of Pi-Cardia’s rigorous clinical program, I am thrilled to see the recognition in the importance of ShortCut™,” said Philippe Genereux, MD from Morristown Medical Center in New Jersey.
  • “Lifetime management of aortic stenosis calls for leaflet modification solutions like ShortCut™ to ensure that we are carefully addressing the risk of coronary obstruction before implanting a valve.

Pi-Cardia Hires Gary Gratson to Lead Global Commercialization

Retrieved on: 
Monday, December 11, 2023
Cardiology, Biotechnology, Other Communications, Health, Marketing, Medical Devices, Communications, Other Health, TAVR, Heart, TMVR, Risk, Percutaneous aortic valve replacement, Patient, Multimedia, Hemodynamics, Aortic stenosis, Growth, Physician, Medical device

Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it hired Gary Gratson to lead commercial operations for ShortCut™, the world's first dedicated leaflet modification device to enable Transcatheter Aortic Valve Replacement (TAVR) in patients at risk of coronary obstruction.

Key Points: 
  • Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it hired Gary Gratson to lead commercial operations for ShortCut™, the world's first dedicated leaflet modification device to enable Transcatheter Aortic Valve Replacement (TAVR) in patients at risk of coronary obstruction.
  • This announcement comes after completion of enrollment in the ShortCut™ Pivotal Study in the US and Europe in September 2023.
  • In his new role, Mr. Gratson will be responsible for building and leading the US commercial organization, driving strategic initiatives, and contributing to the continued growth of Pi-Cardia.
  • "I am honored to join Pi-Cardia at such exciting times,” said Mr. Gratson.

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Retrieved on: 
Thursday, December 7, 2023
General Health, Health, Cardiology, TAVR, Corporation, NYSE, Tricuspid valve, Investment, Surgery, Percutaneous aortic valve replacement, Patient, CE marking, PASCAL, PROGRESS, Conference, CLASP, Aortic stenosis, Growth, Development, TCT, Edwards Lifesciences, Critical care, Pharmaceutical industry, Nursing, Pet industry, Management

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.

Key Points: 
  • Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.
  • Continued progress across these areas will result in more patients diagnosed and treated with Edwards’ repair and replacement technologies, and a significant long-term growth opportunity.
  • Also in 2024, Edwards expects to accelerate its surgical mitral leadership with the global commercialization of its MITRIS RESILIA valve.
  • During the conference, Edwards’ management will reaffirm the company’s 2023 financial guidance and provide guidance for 2024.

Pi-Cardia Successfully Completes Enrollment in Pivotal Study for ShortCut™

Retrieved on: 
Wednesday, September 20, 2023
Medical Devices, Health, Surgery, Other Health, Cardiology, Biotechnology, CT, TMVR, Workflow, DRS, Heart, TCT, Aortic stenosis, Percutaneous aortic valve replacement, Patient, Risk, Hemodynamics, TAVR, Growth, Medical device

Pi-Cardia Ltd ., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today the successful completion of its ShortCut™ Pivotal Study enrollment.

Key Points: 
  • Pi-Cardia Ltd ., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today the successful completion of its ShortCut™ Pivotal Study enrollment.
  • The study was conducted across 20 of the world’s leading TAVR centers in the US and Europe and was led by Drs.
  • Susheel Kodali (New York Presbyterian/Columbia University, New York, USA), Didier Tchétché (Clinique Pasteur, Toulouse, France) and Danny Dvir (Sha’are Zedek, Jerusalem, Israel).
  • "We are excited to have been able to complete enrollment in such a groundbreaking study so efficiently,” said Dr. Kodali.

Ochsner Medical Center Ranked #1 in Louisiana for the 12th Consecutive Year by U.S. News & World Report

Retrieved on: 
Tuesday, August 1, 2023
U.S. News & World Report Best Hospitals Rankings, ENT, OMC, Surgeon, Kidney failure, Prostate cancer, Audiology, Nation, Ochsner Health System, Hospital, Lymphoma, Nursing, Ochsner Medical Center – West Bank, Annals of Pediatric Cardiology, Chronic obstructive pulmonary disease, Otorhinolaryngology, Percutaneous aortic valve replacement, Nose, Pulmonology, MD, Patient, Physician, Journal of Neurology, Neurosurgery, and Psychiatry, Cardiology, Diabetes, Heart failure, Ochsner Baptist Medical Center, Digestive system surgery, Ear, News, Pharmaceutical industry, Pneumonia, Stroke, U.S. News & World Report, U.S, Leukemia

NEW ORLEANS, Aug. 1, 2023 /PRNewswire/ -- Ochsner Medical Center - New Orleans (OMC), inclusive of Ochsner Medical Center- West Bank and Ochsner Baptist, has been named by U.S. News & World Report to its 2023-2024 Best Hospitals, marking the 12th consecutive year ranked as the Best Hospital in Louisiana. Additionally, OMC is the #1 hospital in the New Orleans metro area. Ochsner is also home to U.S. News' top-ranked hospital for kids in Louisiana – Ochsner Hospital for Children.

Key Points: 
  • NEW ORLEANS, Aug. 1, 2023 /PRNewswire/ -- Ochsner Medical Center - New Orleans (OMC), inclusive of Ochsner Medical Center- West Bank and Ochsner Baptist , has been named by U.S. News & World Report to its 2023-2024 Best Hospitals , marking the 12th consecutive year ranked as the Best Hospital in Louisiana.
  • Ochsner is also home to U.S. News' top-ranked hospital for kids in Louisiana – Ochsner Hospital for Children .
  • Ochsner Medical Center - New Orleans (OMC) has been named by U.S. News & World Report to its 2023-2024 Best Hospitals.
  • As part of the annual review, Ochsner hospitals also received more than 30 additional accolades from U.S. News, including Ochsner Lafayette General Medical Center (OLGMC), inclusive of Ochsner Lafayette General Surgical Hospital , Ochsner Lafayette General Orthopedic Hospital and Ochsner Cancer Center of Acadiana , ranking as the best hospital in Southwestern Louisiana.

U.S. News & World Report Names Deborah® a High Performing Hospital in Five Specialties

Retrieved on: 
Tuesday, August 1, 2023
COPD, Heart, Human, Condition, CMS, Centers for Medicare & Medicaid Services, Society of Thoracic Surgeons, Patient satisfaction, Hospital, Research, Chronic obstructive pulmonary disease, Lung, Medicare, Deborah Heart and Lung Center, Percutaneous aortic valve replacement, U.S. News & World Report Best Hospitals Rankings, Patient, TAVR, Heart failure, LVAD, Diagnosis, Health, News, Dentistry, Nursing, U.S. News & World Report

BROWNS MILLS, N.J., Aug. 1, 2023 /PRNewswire/ -- Deborah Heart and Lung Center is a 2023-2024 High Performing Hospital in five specialties, Heart Attack, Heart Bypass Surgery, Heart Failure, Chronic Obstructive Pulmonary Disease (COPD) and Transcatheter Aortic Valve Replacement (TAVR).

Key Points: 
  • That's according to U.S. News & World Report, the global authority in hospital rankings and consumer advice.
  • High Performing is the rating recognizing "care that was significantly better than the national average."
  • Deborah's High Performing rating in five key specialties affirms Deborah's standing as a nationally recognized cardiac center of excellence," Chirichella said.
  • Hospitals that are High Performing have excelled in providing high quality care in specific procedures and/or conditions."

Biological Tissue Valve Segment Surges in the Global Transcatheter Heart Valve Market, Projected to Witness Rapid Growth by 2030

Retrieved on: 
Friday, July 28, 2023
Prevalence, Health, Ageing, Research, TAVI, Aortic stenosis, Percutaneous aortic valve replacement, Patient, Physician, Risk, Tissue engineering, Aortic valve, TAVR, Growth, Abdominal ultrasonography, Valvular heart disease, Medical device, Medical imaging

Aortic stenosis, a condition characterized by the incomplete opening of the aortic valve, has driven the need for transcatheter aortic valve implantation.

Key Points: 
  • Aortic stenosis, a condition characterized by the incomplete opening of the aortic valve, has driven the need for transcatheter aortic valve implantation.
  • Transcatheter Aortic Valve Replacement (TAVR) has emerged as the leading procedure in the global medical market, capturing the highest market share.
  • Rapid Growth of Biological Tissue Market Segment:
    Within the Transcatheter Aortic Valve Replacement (TAVR) industry, the biological tissue market is experiencing rapid growth and emerging as the fastest-growing segment.
  • In conclusion, the global transcatheter heart valve market is set for significant growth, reaching an estimated value of US$ 15.14 Billion by 2030.